The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonneville, M.
Right arrow Articles by Soulillou, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonneville, M.
Right arrow Articles by Soulillou, J. P.

The Journal of Immunology, Vol 141, Issue 12 4187-4195, Copyright © 1988 by American Association of Immunologists

ARTICLES

T lymphocyte cloning from rejected human kidney allograft. Recognition repertoire of alloreactive T cell clones

M Bonneville, JF Moreau, E Blokland, J Pool, JP Moisan, E Goulmy and JP Soulillou
Institut National de la Sante et de la Recherche Medicale, Unite 211, Nantes, France.

We analyzed the recognition repertoire of 16 human alloreactive T cell clones (ATLC) derived from cells invading an irreversibly rejected kidney allograft. These clones, which specifically proliferated against the kidney donor B lymphoblastoid cell line, fell into two classes: CD4+ killers and CD8+ killers. Cytotoxic and proliferative activities of the ATLC were studied by using a panel of allogeneic cells sharing HLA specificities with kidney donor cells. Moreover, mAb recognizing monomorphic parts of HLA class I and class II molecules were used in blocking experiments of ATLC cytotoxicity. The results obtained from proliferative and cytotoxic assays were concordant. All ATLC investigated were directed against HLA molecules, and some clones were found to recognize HLA-B, -C, -DP, -DQ, or -DR products. All anti-HLA class I ATLC were CD8+, whereas both CD4+ and CD8+ ATLC were committed against HLA class II specificities. Nine of 16 ATLC were shown to react against serologically defined donor HLA determinants. These data indicate the recognition of HLA determinants in the course of an in vivo alloimmune response and particularly emphasize the role of HLA-C and DP loci products so far ignored in clinical transplantation.


This article has been cited by other articles:


Home page
 BloodHome page
B. E. Shaw, S. G.E. Marsh, N. P. Mayor, N. H. Russell, and J. A. Madrigal
HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants
Blood, February 1, 2006; 107(3): 1220 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Sharland, A. Patel, J. H. Lee, A. E. Cestra, S. Saidman, and G. L. Waneck
Genetically Modified HLA Class I Molecules Able to Inhibit Human NK Cells Without Provoking Alloreactive CD8+ CTLs
J. Immunol., April 1, 2002; 168(7): 3266 - 3274.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
J. van Rood and F. Claas
The influence of allogeneic cells on the human T and B cell repertoire
Science, June 15, 1990; 248(4961): 1388 - 1393.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.